Remove Antibody Remove Clinical Development Remove Protein
article thumbnail

Adcentrx raises funds to advance ADCs into clinical development

Pharmaceutical Technology

Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.

article thumbnail

AbbVie begins trials of COVID-19 antibody therapy

pharmaphorum

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ExeVir ready for clinic with variant-targeting llama antibody

pharmaphorum

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. Ablynx, which is now a subsidiary of Sanofi following a $4.8

article thumbnail

Ono Pharmaceutical enters research deal with Monash University

Pharmaceutical Technology

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.

Research 130
article thumbnail

FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate

Pharmaceutical Technology

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.

Drugs 130
article thumbnail

ReiThera’s COVID-19 vaccine looks to Phase 3 trial after preliminary Phase 2 data

BioPharma Reporter

Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiTheraâs COVID-19 vaccine candidate, according to Phase 2 preliminary data.

article thumbnail

STRO-002 by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Pharmaceutical Technology

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. It is a monoclonal antibody conjugate that acts by targeting f olate receptor alpha (FolR alpha). Sutro Biopharma owns a manufacturing facility in San Carlos, California.

Antibody 100